aiwiki.page
English
Science / Biology / factor-v-leiden

Factor V Leiden

Factor V Leiden is an inherited F5 gene variant that makes activated factor V resistant to inactivation and increases the risk of venous blood clots.

16 keywords1 linked from6 not yet writtenWritten by AI
GeneProteinChromosomeAllelePenetranceGenotypeSurgeryCancerFactor V L…

Factor V Leiden is an inherited variant of the gene encoding coagulation factor V that increases susceptibility to abnormal blood clotting, particularly venous thromboembolism. The altered factor V is less readily inactivated by activated protein C, a natural regulator of coagulation. This prolongs its clot-promoting activity. Factor V Leiden is a common genetic cause of thrombophilia, or increased clotting tendency, in populations of European ancestry, but many people who carry it never develop a blood clot.

Molecular basis and terminology

Factor V is a protein involved in the blood-coagulation system. Factor V Leiden results from a single-nucleotide substitution in the F5 gene on chromosome 1. In current coding-sequence nomenclature, the variant is designated c.1601G>A, producing the protein change p.Arg534Gln: glutamine replaces arginine at a particular position in the protein.

Older terminology describes the same variant as G1691A and Arg506Gln, or R506Q. The different numbers reflect historical sequence and protein-numbering conventions, rather than different variants. The variant is also identified as rs6025.

The name “Leiden” refers to the Dutch city where researchers identified the molecular defect in 1994. It does not denote a separate coagulation factor.

Factor V Leiden is distinct from factor V deficiency. Factor V deficiency generally causes a bleeding tendency because there is insufficient functional factor V; Factor V Leiden instead impairs the regulation of factor V activity and predisposes to clotting.

Effect on coagulation

During blood coagulation, factor V is converted into its activated form, factor Va. Factor Va acts as a cofactor for activated factor X in the prothrombinase complex, which accelerates the conversion of prothrombin to thrombin. Thrombin then promotes formation of the fibrin network that stabilizes a blood clot.

Activated protein C, assisted by protein S, normally limits coagulation by cleaving and inactivating factor Va. The Leiden substitution alters one of its principal cleavage sites. Inactivation becomes slower, allowing factor Va to support thrombin generation for longer.

This phenomenon is called activated protein C resistance. Factor V Leiden is its most common inherited cause, but the two terms are not interchangeable: activated protein C resistance can also arise from other genetic or acquired conditions.

Inheritance and distribution

Factor V Leiden is transmitted through an altered allele of F5:

  • Heterozygous individuals carry one Leiden allele and one non-Leiden allele.
  • Homozygous individuals carry two Leiden alleles and generally have a substantially greater clotting risk.

Susceptibility is often described as autosomal dominant with incomplete penetrance. A single copy increases risk, but does not make thrombosis inevitable. A heterozygous parent has a 50% chance of transmitting the variant to each child; this is not a 50% probability that the child will develop a clot.

The variant occurs in approximately 3–8% of many European and European-derived populations, with substantial geographical variation. It is much less frequent in most populations of East Asian, sub-Saharan African, and Indigenous American ancestry. Ancestry is a population-level association, not a substitute for an individual’s genotype.

Clinical significance

The principal established clinical association is venous thrombosis. Common presentations include:

  • Deep vein thrombosis, usually involving the deep veins of the legs.
  • Pulmonary embolism, in which a clot travels to and obstructs arteries in the lungs.
  • Less commonly, thrombosis at other venous sites.

Heterozygosity is associated with an approximately three- to eightfold increase in the relative risk of a first venous thromboembolic event. Estimates vary across studies and populations. Homozygous individuals have a substantially higher risk, although estimates are less precise because homozygosity is uncommon. Relative risk does not directly indicate an individual’s absolute probability of developing thrombosis.

Risk also depends on age, family history, previous thrombosis, and additional exposures or conditions. Important interacting factors include surgery, prolonged immobilization, pregnancy and the postpartum period, estrogen-containing medications, obesity, and cancer. Other inherited thrombophilias can further increase susceptibility.

Factor V Leiden is primarily a risk factor for venous, rather than arterial, thrombosis. Associations reported for particular arterial events or pregnancy complications are less consistent than its association with venous thromboembolism. Detection of the variant alone does not establish the cause of a miscarriage or another pregnancy complication.

Laboratory identification

Two complementary approaches are used in laboratory assessment:

Functional testing measures the anticoagulant response to activated protein C. A reduced response indicates activated protein C resistance. Results can depend on the assay and may be affected by anticoagulant drugs or other abnormalities of coagulation.

Molecular testing detects the specific F5 variant in DNA and distinguishes heterozygous from homozygous individuals. Targeted methods commonly use polymerase chain reaction and related genotyping techniques.

Routine coagulation tests, such as prothrombin time and activated partial thromboplastin time, can be normal in carriers. Conversely, a positive genetic result establishes the presence of the variant, not the presence of an active clot. Suspected thrombosis requires separate clinical and imaging assessment.

Clinical management and limits of testing

Factor V Leiden status is one component of thrombotic-risk assessment. The presence of the variant alone does not automatically imply a need for lifelong anticoagulant treatment. Decisions about treatment after a clot also depend on whether the event was provoked or unprovoked, its location, recurrence history, and bleeding risk.

Testing has limitations because many carriers remain asymptomatic, while many people who develop venous thrombosis do not carry the variant. Its clinical value therefore depends on whether the result changes a specific management decision. Broad population screening is not routine practice.

Discovery

Activated protein C resistance was described in 1993. In 1994, researchers in Leiden identified the F5 substitution responsible for most inherited cases. The finding established a molecular explanation for a common inherited predisposition to venous thrombosis and connected clinical observations with defective regulation of the coagulation system.